The overexpression of CRM1 is considered a prediction factor for the poor prognosis of AML patients [38], and recent studies show that the combination of KPT-330 with daunorubicin and cytarabine results in increased responses of AML patients to therapy [32,33,34]. The gene discussed is XPO1; the disease is acute myeloid leukemia.